Press Releases

Dr. Arron brings nearly two decades of scientific leadership in biotech drug discovery and development to 23andMe’s Therapeutics team SUNNYVALE, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company, today

SUNNYVALE, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it will redeem all of its outstanding warrants (the “Public Warrants”) to purchase shares of Class A common stock of 23andMe that

Second quarter revenue of $55 million Recent addition of telemedicine platform further advances vision of individualized primary care that empowers consumers to live healthier lives SUNNYVALE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer

SUNNYVALE, Calif. , Nov. 9, 2021 /PRNewswire/ --  23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, announced today that management will be presenting at three upcoming virtual investor conferences:     Credit Suisse 30th Annual Healthcare Conference on

SUNNYVALE, Calif. , Nov. 9, 2021 /PRNewswire/ --  23andMe Holding Co. (Nasdaq: ME) (" 23andMe "), a leading consumer genetics and research company, today announced the appointment of Dr. Sandra Hernández, President & CEO of the California Health Care Foundation ("CHCF"), to its Board of Directors.

SUNNYVALE, Calif. , Nov. 03, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 second quarter after market closes on Wednesday, November 10, 2021 .

SUNNYVALE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it has completed its previously-announced acquisition of Lemonaid Health, Inc. (“Lemonaid Health”), an on-demand platform for

Acquisition provides telemedicine platform for 23andMe to advance its vision of individualized primary care that empowers consumers to live healthier lives 23andMe to host investor webcast today at 10:00 AM ET    SUNNYVALE, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co.

SUNNYVALE, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 second quarter after market closes on Wednesday, November 10, 2021.

SUNNYVALE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that management will be participating in the Wells Fargo Virtual Healthcare Conference on Friday, September 10, 2021 at 8:20 a.m.